Predictors of visual outcome after successful rhegmatogenous retinal detachment repair are identified

Article

Important predictors of postoperative visual outcome after successful successful rhegmatogenous retinal detachment repair have been identified.

Important predictors of postoperative visual outcome after successful successful rhegmatogenous retinal detachment repair have been identified in a study published in Retina.

Dr Magda Gharbiya et al., Department of Ophthalmology, University of Rome, Italy, included 35 patients with preoperative macula-on rhegmatogenous retinal detachment or macula-off rhegmatogenous retinal detachment. All patients underwent scleral buckling surgery and the Early Treatment Diabetic Retinopathy Study was used to measure best-corrected visual acuity (BCVA). Microperimetry and SD-OCT were also conducted on the same day.

SD-OCT was used to measure foveal centre retinal thickness, central 1 mm subfield thickness and outer nuclear layer thickness. The team also assessed the presence or absence of epiretinal membrane, intraretinal fluid and subretinal fluid.

Additionally, the investigation determined the intermediate line as disrupted or complete and identified the status of the external limiting membrane and the inner/outer segment junction. Correlations between SD-OCT findings and postoperative BCVA or retinal sensitivities for central 12° were evaluated.

SD-OCT retinal measurements of the outer nuclear layer thickness strongly correlated with postoperative BCVA and retinal sensitivities. BCVA was also highly correlated with the status of the external limiting membrane, inner/outer segment junction and intermediate line.

Outer nuclear layer thickness and the status of the intermediate line were identified as the most important predictors of visual outcome, as multivariate analysis demonstrated.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.